Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a skin condition called moderate to severe plaque psoriasis. It enrolled 1,831 participants across four groups: 612 people received brodalumab at a 210 mg dose, 610 received brodalumab at a 140 mg dose, 300 received ustekinumab (another existing treatment used for comparison), and 309 received a placebo (an inactive injection). The trial measured three things at the 12-week mark: a doctor's overall impression of the skin (called the sPGA score), the proportion of participants whose psoriasis area and severity improved by at least 75% (PASI 75), and the proportion whose psoriasis cleared completely (PASI 100). The reported data shows the following participant counts meeting each measure at week 12. For the doctor's overall skin assessment (sPGA), the numbers recorded as "clear or almost clear" were: 481 out of 612 in the 210 mg brodalumab group, 354 out of 610 in the 140 mg brodalumab group, 183 out of 300 in the ustekinumab group, and 12 out of 309 in the placebo group. For the 75% improvement measure (PASI 75), the reported numbers were 528, 406, 210, and 25 respectively across the same groups. For complete clearance (PASI 100), the reported numbers were 272, 157, 65, and 2 respectively. The data does not include the percentage figures themselves, only the raw participant counts. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39264399) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have had moderate to severe plaque psoriasis that has been stable for at least 6 months.
- At the screening and start of the trial, your psoriasis affects at least 10% of your body surface area and scores highly enough on two standard psoriasis severity measurement scales (confirm with trial site for exact score details).
Who may not be able to join:
- You have been diagnosed with a specific type of psoriasis other than plaque psoriasis (such as pustular, guttate, or erythrodermic psoriasis), psoriasis caused by medication, or another skin condition like eczema that could affect study results.
- You have a known history of Crohn's disease.
- You have another significant ongoing medical condition or abnormal lab results, as outlined in the study rules (confirm with trial site).
- You have not stopped using certain psoriasis treatments within the required timeframe before joining (confirm with trial site for which treatments and how long before).
- You have previously been treated with ustekinumab or any anti-IL-17 biologic therapy (a specific type of medication that targets the immune system).
- You are currently pregnant, breastfeeding, or planning to become pregnant during the study.
- You are a woman who is unwilling to use highly effective contraception, unless you have been through menopause for at least 2 years or have had a surgical procedure that prevents pregnancy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12; Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12; Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.